AR038381A1 - N-ALILOXIETIL-1,2,3,4,5,6-HEXAHYDRO-2,6-METHANE-3-BENZAZOCINAS AND ITS USE AS A MEDICINAL PRODUCT - Google Patents

N-ALILOXIETIL-1,2,3,4,5,6-HEXAHYDRO-2,6-METHANE-3-BENZAZOCINAS AND ITS USE AS A MEDICINAL PRODUCT

Info

Publication number
AR038381A1
AR038381A1 ARP030100290A ARP030100290A AR038381A1 AR 038381 A1 AR038381 A1 AR 038381A1 AR P030100290 A ARP030100290 A AR P030100290A AR P030100290 A ARP030100290 A AR P030100290A AR 038381 A1 AR038381 A1 AR 038381A1
Authority
AR
Argentina
Prior art keywords
ethyl
mean
methyl
hexahydro
methane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ARP030100290A
Other languages
Spanish (es)
Inventor
Carter Adrian Dr
Ensinger Helmut Dr
Grauert Matthias Dr
Stiller Detlef Andre Dr
Weiser Thomas Dr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR038381A1 publication Critical patent/AR038381A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Se refiere a 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles de fórmula general (1), procedimientos para su preparación, así como a su uso como medicamentos en los cuales el bloqueo del canal de sodio dependiente de la tensión puede desplegar una utilidad terapéutica. Reivindicación 1: Compuesto de fórmula general (1) en la que R1, R2 y R3, iguales o diferentes, pueden significar H, metilo o etilo; R4 puede significar H, metilo o etilo; R5, R6 y R7, iguales o diferentes, pueden significar H, metilo o etilo; R8 y R9, iguales o diferentes, pueden significar H, F, Cl, Br, metilo, etilo, hidroxi o metoxi, eventualmente en forma de sus racematos, sus enantiómeros, sus diaestereoisómeros y sus mezclas, así como, eventualmente, de sus sales por adición de ácidos farmacológicamente inocuas.It refers to 1,2,3,4,5,6-hexahydro-2,6-methane-3-benzazocin-10-oles of general formula (1), procedures for its preparation, as well as its use as medicaments in which the tension-dependent sodium channel block can display a therapeutic utility. Claim 1: Compound of general formula (1) wherein R1, R2 and R3, the same or different, can mean H, methyl or ethyl; R4 can mean H, methyl or ethyl; R5, R6 and R7, the same or different, may mean H, methyl or ethyl; R8 and R9, the same or different, may mean H, F, Cl, Br, methyl, ethyl, hydroxy or methoxy, possibly in the form of their racemates, their enantiomers, their diastereoisomers and mixtures thereof, as well as, eventually, their salts by the addition of pharmacologically safe acids.

ARP030100290A 2002-02-02 2003-01-31 N-ALILOXIETIL-1,2,3,4,5,6-HEXAHYDRO-2,6-METHANE-3-BENZAZOCINAS AND ITS USE AS A MEDICINAL PRODUCT Withdrawn AR038381A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10204276A DE10204276A1 (en) 2002-02-02 2002-02-02 N-Allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
AR038381A1 true AR038381A1 (en) 2005-01-12

Family

ID=7713598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100290A Withdrawn AR038381A1 (en) 2002-02-02 2003-01-31 N-ALILOXIETIL-1,2,3,4,5,6-HEXAHYDRO-2,6-METHANE-3-BENZAZOCINAS AND ITS USE AS A MEDICINAL PRODUCT

Country Status (10)

Country Link
EP (1) EP1474398A1 (en)
JP (1) JP2005517013A (en)
AR (1) AR038381A1 (en)
AU (1) AU2003215540A1 (en)
CA (1) CA2474687A1 (en)
DE (1) DE10204276A1 (en)
PE (1) PE20030991A1 (en)
TW (1) TW200303203A (en)
UY (1) UY27637A1 (en)
WO (1) WO2003066599A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7804509A (en) * 1978-04-26 1979-10-30 Acf Chemiefarma Nv Novel 6,7-benzomorphan derivatives and their acid addition salts.
DE4121821A1 (en) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg NEW BENZOMORPHANE AND ITS USE AS A MEDICAMENT
DE4122141C2 (en) * 1991-07-04 1999-05-27 Porsche Ag Exhaust pipe of an internal combustion engine
DE19740110A1 (en) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma New hydroxy substituted benzomorphan derivatives
DE19907874A1 (en) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma New N-substituted hexahydro-2,6-methano-3-benzazocin-10-ol derivatives, as tension-dependent sodium channel blockers useful for treating e.g. arrhythmia, spasms, pain or neurodegenerative diseases
US6245777B1 (en) * 1999-02-23 2001-06-12 Boehringer Ingelheim Pharma Kg N-(5-phenyl-tetrahydrofuranyl)methyl- and N-(6-phenyl-tetrahydropyranyl)methyl-substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols
DE19957156A1 (en) * 1999-11-27 2001-05-31 Boehringer Ingelheim Pharma New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders

Also Published As

Publication number Publication date
AU2003215540A1 (en) 2003-09-02
TW200303203A (en) 2003-09-01
PE20030991A1 (en) 2004-01-27
UY27637A1 (en) 2003-08-29
EP1474398A1 (en) 2004-11-10
DE10204276A1 (en) 2003-08-07
CA2474687A1 (en) 2003-08-14
WO2003066599A1 (en) 2003-08-14
JP2005517013A (en) 2005-06-09

Similar Documents

Publication Publication Date Title
PA8507601A1 (en) NEW BENZOIMIDAZOL USEFUL DERIVATIVES AS ANTIPROLIFERATIVE AGENTS
TW200608972A (en) Aryl-pyridine derivatives
AR054129A1 (en) DERIVATIVES OF 2, 6-QUINOLINILO, A PHARMACEUTICAL PREPARATION THAT CONTAINS THEM AND ITS EMPLOYMENT IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DEPENDENT DISEASES OF INTEGRINES ALFA4BETA1 AND / OR ALFA4BETA7
ECSP055853A (en) NEW DERIVATIVES OF HETEROCICLIC FLUOROGLYCOSIDS, PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS, AND THE USE OF THE SAME
UY27368A1 (en) NEW COMPOUNDS
UY29893A1 (en) PIRAZINE DERIVATIVES
ECSP055633A (en) NEW BENZOIMIDAZOLUTILES DERIVATIVES AS ANTIPROLIFERATIVE ANGENTS
UY27740A1 (en) NEW COMPOUNDS
ECSP066313A (en) DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS
ECSP066315A (en) DERIVATIVES OF PIRIDAZINE AND ITS USE AS THERAPEUTIC AGENTS
CR8859A (en) PIRIDINE DERIVATIVES
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
PA8432901A1 (en) PIRIDILPIRROL COMPOUNDS
CR10376A (en) TERFENIL DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AR048607A1 (en) DERIVATIVES (POLI) AMINOALQUILAMINO ACETAMIDE OF EPIPODOFILOTOXINA, PROCESS OF PREPARATION OF THE SAME AND ITS THERAPEUTIC APPLICATIONS AS ANTICANCEROS AGENTS
AR050260A1 (en) DERIVATIVES OF DIARILMETILPIPERAZINAS, ITS PREPARATION AND ITS USE
UY27803A1 (en) DERIVATIVES OF BENZOXAZINE AND USES OF THE SAME.
ECSP099506A (en) DERIVATIVES OF 2-QUINOLINONA AND 2 QUINOXALINONA AND ITS USE AS ANTI BACTERIAL AGENTS
AR025046A1 (en) IL-5 NON-STEROID INHIBITORS, PROCEDURES AND INTERMEDIARIES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITORS
PA8581701A1 (en) INDOLILO DERIVATIVES
UY27930A1 (en) DERIVATIVES OF TIAZOL
ECSP099679A (en) NEW COMPOUNDS AND THEIR USES 707
PE20021016A1 (en) PREGABALIN-LACTOSE CONJUGATES
AR029666A1 (en) USE OF (+) -ALFA- (2,3-DIMETOXIFENIL) -1- [2- (4-FLUOROPHENYL) ETHYL] -4-PIPERIDINMETHANOL OR ITS DRUG FOR THE MANUFACTURE OF A MEDICINAL PRODUCT IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND OF PSYCHOSIS INDUCED BY DOPAMINE
AR038381A1 (en) N-ALILOXIETIL-1,2,3,4,5,6-HEXAHYDRO-2,6-METHANE-3-BENZAZOCINAS AND ITS USE AS A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal